The clinical outcome of neuroblastoma patients is good for early stages (I-II) with minimal disease below the age of 1 year and for stage IV-S. However stages III and IV over 1 year of age experience a very poor prognosis. Shimada et al. (1984) first explored the relationship between morphologic differentiation and prognosis. Schwab et al. (1983) related N-myc amplification with morphologic differentiation, and Brodeur and Seeger (1986) produced clinical evidence for a connection between N-myc amplification and prognosis. The gene changes presumed to induce or to contribute to tumour initiation and progression may be associated with cytogenetic abnormalities as already reported for other tumours (Klein 1983; Canaani et al., 1984) . At a simple level of analysis, both Look et al. (1984) and Gansler et al. (1986) related the DNA content of neuroblastoma cells to prognosis. A more favourable clinical outcome was associated with a hyperdiploid situation. Kaneko et al. (1987) attempted to relate various karyotypic patterns, characteristic of neuroblastoma, to prognosis.
Partial monosomy of the short arm of chromosome 1 was reported as the most common aberration in human neuroblastomas (Brodeur et al., 1981; Gilbert et al., 1984) . Recently it has been postulated that this chromosomal alteration might be typical of patients at stages III and IV (Franke et al., 1986) . On the same arm of chromosome 1, three common fragile sites were mapped in lp22, lp3l-32, 1p36 (Berger et al., 1985) . Hecht and Glover (1984) showed that the localisation of fragile sites and tumour breakpoints in the same chromosomal bands is not random.
The amplification of the oncogene N-myc characterizes the most advanced stages of the disease (III, IV) . This gene has been mapped on chromosome 2 (2p23-24) (Schwab et al., 1983) , however, its amplification is often localised in homogeneously staining regions (HSR) on different chromosomes, or in double minutes (dms).
Here we describe the cytogenetic and immunochemical characterization of a case of disseminated neuroblastoma in a 15 month old boy. This report produces evidence of (i) a translocation involving 2p24, (ii) increased expression of fragile site lp31-32 in the patient's normal lymphocytes corresponding to a deletion in the tumour cells, an association described for the first time at this site, (iii) high incidence of fragile sites in normal lymphocytes, in both the patient and his mother. (Sugimoto et al., 1984) . UJ308 antibody was used as positive control for its ability to bind bone marrow cells. The negative control was treated only with the second antibody. Following two washes in PBS-azide (1 mM) a second incubation was performed for 20 min at room temperature with 40 4ul FITC-labelled goat anti-mouse immunoglobulin antibody (Cappell, USA). Two further washes in PBS-azide were performed before analysing the fluorescence under a Leitz Dialux 22 UV-light microscope or on a FACS-analyser (Becton-Dickinson, USA) flow cytometer.
Patient and methods

Case
Cell culture Tumour cells were harvested from the bone marrow by gradient, as described above. Washed nucleated cells, approximately 5 x 106, were seeded on 25cm2 flasks pretreated with collagen for 3 h and then transferred into new flasks. Cultures were performed at 37°C in a humidified incubator in the presence of 5% C02, using RPMI 1640 supplemented with 10% v/v heat-inactivated foetal calf serum, 2 mM L-glutamine, 2 g 1-1 Na-bicarbonate, 5 mM HEPES, 1% v/v non-essential amino acids, 100 IU ml-1 penicillin and streptomycin. All culture reagents were from Flow Ltd., UK.
Cytogenetics
Bone marrow cells were cultured for 1, 24 or 48 h including 1 h in the presence of 2 pg colchicine ml -(Sigma, USA) and then harvested (Table I) . A parallel sample was synchronised with methotrexate (MTX) (Lederle, UK) as described by Hagemeyer et al. (1979) and harvested at 24 h.
Whole blood cultures from the patient and his parents were performed by stimulation with 2% v/v PHAm (Difco, USA) for 72 h. Some cultures were treated for the last 24 h with 0.04 pgml-1 aphidicolin (APC) (Serva, FRG) or 10 ug MTX ml-1 to induce the expression of common fragile sites.
Chromosomes were obtained by standard techniques, and banded by mild trypsin treatment (Seabright,. 1971) . One hundred metaphases were observed for each culture.
In vitro hybridisation was performed with 2 kbp N-myc Eco RI probe, labelled by nick translation using 3H-dCTP and 3H-dTTP (Amersham, UK) to a specific activity of 3.5 x I07 dpmjg-l. We used the method of Harper and Saunders (1981) as modified by Bartram et al. (1983) . Slides were coated by NTB2 emulsion (Kodak, USA) and exposed in darkness at 4°C for 15-21 days. After development and fixation, chromosomes were stained with Wright's solution (Chandler & Yunis, 1978) .
Grain location was reported on a chromosome ideogram (Yunis, 1981) . x2 analysis was performed to evaluate statistical significance of grain distribution on chromosomes.
weakly positive for UJ13A, and positive for UJ308. The antibodies were able to bind subsequent samples of neuroblastoma and the technique was considered adequate as shown by the UJ308 reactivity. Even though histology and three specific antibodies gave a genuine negative result, the UJ13A reactivity suggested a neuroblastoma infiltration in the bone marrow.
In order to verify the presence of neuroblastoma cells infiltrating the bone marrow with a different approach, we attempted to grow them in culture. Figure 1 shows the tumour cells at the 21st day after seeding. Various neuronallike islets were evident on a fibroblast layer. Many long dendritic processes raised from the central nucleous, connecting other islets. This morphological appearance has been previously described for other primary neuroblastomas in short term culture (Biedler et al., 1978; Ito et al., 1987) . This was conclusive evidence of neuroblastoma infiltration in the bone marrow.
Cytogenetic studies No constitutional aberrations were found in chromosomes from lymphocytes of the patient or his parents.
In bone marrow cells two lines were detected, as indicated in Table I . One with normal karyotype and a second line (see Figure 2) , with a karyotype of 45XY, del (1) (p32), and 2 markers that we interpreted as Mar 1= der (2) t (2; 2) (2qter-+2ql4::2p24-+2qter). Mar 2=der (15) t (15; 2) (l5qter-+ 15pl 1::2pl 1 -+2pter). Three percent of these metaphases showed also dms.
Treatment of bone marrow cells with 5 pg MTX ml 1 led to the unexpected disappearance of almost all cytogenetically abnormal cells (Table I) . The results of the in situ hybridisation with the N-myc probe are shown in Table II . A significant number of grains was localised both in the long arms of marker 1, supposed to contain 2p23-24, and in the short arm of marker 2, supposed to be the short arm of chromosome 2 (Figure 3) . The data confirm the cytogenetic interpretation of the markers. A very high sensitivity to APC and MTX was found in the patient and his mother, while the father showed values comparable to those of our controls, as shown in Table III . A particularly interesting finding was the increased expression of fragile site lp3l-32 in the patient. Twenty-three out of 202 aberrations (11.4%) were located in lp3l-32, while they were 4 out of 174 (2.3%) in normal controls. The distribution of other fragile sites in the patient (data not shown) was not dissimilar from normal controls (Tedeschi et al., 1987 (ISNC, 1981) . bNormal metaphases from PHA-stimulated peripheral blood lymphocytes.
Discussion
Since the data presented in this report demonstrate that neuroblastoma cells were present in the patient's bone marrow aspirate (Figure 1 ), we are justified in considering the abnormal mitoses described as belonging to these abnormal cells. The points of interest shown by the cytogenetic analysis are: (i) One of the translocations described (Mar 1) occurred near the site of the N-myc oncogene at 2p23-24, which is possibly relevant because of the N-myc amplification reported for neuroblastoma. (ii) The normal lymphocytes of the patient expressed a chromatid fragile site in lp3l-32 corresponding to the deletion found in the tumour cells.
(iii) The patient and his mother both expressed an increased incidence of fragile sites. This may possibly be relevant for the transmission of the predisposition to tumour development. Since neuroblastoma cells have a heterogeneity of reactivity, a panel of 4 monoclonal antibodies was used for the immunofluorescence. This method is usually very reliable and sensitive for the identification of neuroblastoma cells since the reactivity of only one antibody may be sufficient for the diagnosis (Kemshead et al., 1983; Sugimoto et al., 1984; . The UJ13A positivity was the only immediate suggestion of neuroblastoma infiltration in the bone marrow. In fact only after 21 days did the cultured cells show the typical morphology of neuroblastoma ( Figure  1 ). This is not the only report of neuroblastoma infiltration in the bone marrow with negative histology (Ito et al., 1987 (Mathew et al., 1987) , according to the '2-hit' hypothesis of Knudson and Meadows (1980) .
Although only few metaphases in the present report had dms, and none had HSRs with amplified N-myc, they showed aberrations in the region containing this protooncogene. This has been confirmed by in situ hybridisation. For this reason we believe that the translocation producing marker 1 might have been important for the neuroblast transformation in this child. Recently, another case of neuroblastoma has been described with specific aberrations involving chromosome 1 in lp22 and chromosome 2 in 2p24 (Christiansen et al., 1987) . Both observations point out that chromosomal band 2p24 containing N-myc is involved in aberrations in neuroblastoma.
The predisposition to tumour development may be transmitted in an heritable fashion (Kushner et al., 1986; McKusick, 1983) . We do not know whether the first 'hit' may be connected with the increased inducibility of the fragile site lp31-32 in the child. Other cases in individual patients showing a particular fragile site expression in lymphocytes, and an aberration involving the same chromosomal area in the tumour have already been described. For example an elevated expression of the 7q31.2 fragile site in 2 patients with ANLL and 7q31.2-q36 deletion in tumour cells. Similarly the increased expression of the 18q21.3 fragile site has been associated with a translocation t (14; 18) (q32.3; q21.3) in a patient with follicular lymphoma; and the fragile site 16q22.1 is related to inv (p13.11 q22.1) on ANLL tumour cells (Yunis & Soreng, 1984) .
The present case is the first report of association between a breakpoint in a tumour and a fragile site induced by APC. Our findings further stress the need of more systematic work on this subject.
Part of the financial support was from MPI grants to BN and to Professor A. Finazzi Agro. We wish to thank Dr Maria Finocchiaro and Mr Graziano Bonelli for their technical assistance, and Cristiana Sinapi for her secretarial help.
References BARTRAM, C.R., KLEIN, A., HAGEMEYER., A. & 10 others (1983) .
Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature, 306, 277.
BERGER, R., BLOOMFIELD, C.D. & SUTHERLAND, G.R. (1985) . Report of the committee on chromosome rearrangements in neoplasia and on fragile sites (HMG8). Cytogenet. Cell Genet., 40, 490.
